a clinically important QoL improvement and a significantly greater improvement than those treated with NIV. However, the average quality of life of those treated with NIV did not decline by a clinically important amount (table 1).

Conclusions On average, patients hospitalised with AECOPD not requiring NIV experience an improvement in QoL following discharge and in those treated with NIV, QoL does not appear to decline. Most patients can expect their quality of life to be no worse than that reported at hospital discharge.

Reference

1. BTS The Use of Non-Invasive Ventilation in the management of patients with chronic obstructive pulmonary disease admitted to hospital with acute type II respiratory failure, 2008.

Abstract P82 Table 1 Mean change in quality of life during follow-up

Mean change in QoL (mean (SD)),†	Total population, n=176	Ventilated, n=80	Not ventilated, n=96	p value*
SGRQ Symptoms	-8.65 (19.5)	-4.80 (19.4)	-11.8 (19.2)	0.017
SGRQ Activity	1.79 (12.0)	3.22 (10.2)	0.60 (13.3)	0.15
SGRQ Impacts	-2.98 (15.4)	-0.09 (15.5)	-5.36 (14.9)	0.024
SGRQ Total	-2.47 (13.0)	0.05 (12.5)	-4.55 (13.2)	0.019

* comparison between ventilated and not ventilated groups; † lower values indicate improved quality of life, minimally important clinical difference = ±4

P83 RELATIONS OF DIFFERENT QUALITY OF LIFE TOOLS TO SUBSEQUENT MORTALITY AND READMISSION OF PATIENTS SURVIVING HOSPITALISATION FOR ACUTE EXACERBATIONS OF COPD

doi:10.1136/thoraxjnl-2012-202678.325

¹J Steer, ²GJ Gibson, ¹SC Bourke. ¹North Tyneside General Hospital, North Shields, United Kingdom; ²Newcastle University, Newcastle-upon-Tyne, United Kingdom

Background In patients hospitalised with acute exacerbations of COPD (AECOPD), quality of life (QoL) scores have been associated with subsequent mortality and readmission. We have investigated which of several QoL indices are most closely related to subsequent outcome.

Methods 183 patients with AECOPD surviving to hospital discharge were identified prospectively. Baseline clinical information and subsequent mortality and readmission over 12 months were recorded. QoL was assessed at discharge using: the St. George's Respiratory Questionnaire (SGRQ); the Chronic Respiratory Questionnaire (CRQ); the Hospital Anxiety and Depression Scale (HADS); and the Nottingham Extended Activities of Daily Living Scale (NEADL) and relationships between QoL and each outcome were analysed.

Abstract P83 Table 1 Quality of life at discharge and subsequent outcome

Quality of life measurement	Died, n=33	Survived, n=150	p value	Readmitted, n=130	Not readmitted, n=53	p value
SGRQ, mean (SD)†						
Symptoms	63.3 (20.8)	66.7 (19.7)	0.38	66.3 (19.5)	65.6 (20.8)	0.85
Activity	85.0 (12.8)	77.9 (16.3)	0.021	81.1 (14.8)	74.6 (17.8)	0.012
Impacts	55.7 (19.1)	48.9 (19.8)	0.071	51.4 (20.5)	47.1 (17.6)	0.19
Total	65.6 (15.2)	60.7 (17.1)	0.13	62.6 (17.6)	59.1 (14.9)	0.21
CRQ, median (IQR)‡						
Dyspnoea	2.8 (1.7 to 4.1)	2.8 (2.15 to 3.8)	0.56	2.8 (2 to 4)	2.8 (2 to 3.6)	0.46
Emotional function	2.3 (1.5 to 3)	2.4 (1.5 to 3.3)	0.83	3.4 (2.4 to 4.9)	3.6 (2.4 to 4.8)	0.90
Fatigue	3.7 (2.65 to 4.4)	3.4 (2.38 to 4.9)	0.69	2.3 (1.5 to 3)	2 (1.3 to 3.2)	0.56
Mastery	3 (2.15 to 4.15)	3.3 (2.2 to 4.5)	0.60	3 (2.3 to 4.3)	3.3 (1.8 to 4.9)	0.92
HADS, median (IQR)†						
Anxiety	8 (5 to 12.5)	8 (4 to 14)	0.93	8 (4 to 14)	9 (4.5 to 13)	0.83
Depression	8 (5 to 10.5)	6 (3 to 9)	0.082	6 (3 to 10)	6 (3 to 8)	0.37
NEADL, median (IQR)‡						
	28 (14 to 37)	38 (28 to 45)	<0.001	34 (24 to 42)	42 (33 to 51)	0.001

†Lower values indicate improved quality of life; ‡Higher values indicate improved quality of life. SGRQ – St George's Respiratory Questionnaire; CRQ – Chronic Respiratory Disease Questionnaire; HADS – Hospital Anxiety and Depression Scale; NEADL – Nottingham Extended Activity of Daily Living Scale.

Results Mean (SD) age was 69.0 (9.0) years and most patients: were female (58.5%); had severe airflow obstruction (mean (SD) FEV₁ 40.2 (17.3) % predicted); and were of normal weight (mean (SD) BMI 26.2 (7.0) kgm⁻²).

130 (71%) patients were readmitted during the year following discharge, with a median number of readmissions of 1 (IQR 0 to 3; range 0 to 15). The mortality rates at 3, 6 and 12 months following discharge were 6.6%, 10.4% and 18.0% respectively.

Self-reported measures of activity (SGRQ Activity and NEADL) were the only QoL indices significantly associated with both mortality and readmission. The relations of SGRQ Impacts and HADS Depression to mortality showed nonsignificant trends, but no other QoL domains were associated with readmission (table 1).

Conclusion Measures of self-reported activity at discharge were the most closely associated with both subsequent mortality and readmission and are likely to be the most useful of the QoL indices studied for predicting clinical outcome.

P84 UTILITY VALUES FOR COPD PATIENTS BASED ON THE EQ-5D QUESTIONNAIRE FROM THREE INDACATEROL PHASE III STUDIES

doi:10.1136/thoraxjnl-2012-202678.326

¹Y Asukai, ²M Baldwin, ¹L Mungapen. ¹IMS Health Economics and Outcomes Research, London, United Kingdom; ²Novartis Pharmaceuticals, Horsham, United Kingdom

Introduction and Objectives Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully reversible and disabling symptoms such as breathlessness and COPD exacerbations, which have a negative impact on health-related quality of life (HRQoL). The indacaterol clinical trial programme (INVOLVE, INHANCE and INLIGHT-2 trials) collected HRQoL using the EuroQoL (EQ-5D) instrument, a commonly used tool to generate preference-based utilities involving five dimensions of a health state. As part of the clinical trial programme, the EQ-5D scores were converted to a utility index score using the UK National Health Survey (1) preference weights. The aim of this analysis was to report mean utilities of COPD patients by disease severity.

Methods A total of 11,066 observations from three trials were included in the analysis. Utility index scores were summarised by disease severity (GOLD 2008 FEV1-based) to yield a mean utility weight for each disease severity class. Disease severity was determined by using all available FEV1 readings. Since some trials had a longer duration contributing more records of EQ-5D and spirometry than others, it was necessary to correct for multiple observations; utility values that might have been derived from the shorter-duration trials were considered as 'missing' data. To impute

missing data, a mixed effects model was used using residual maximum likelihood. Clinic visit and disease severity were included as factors. Utility values were assumed to be missing at random.

Results The estimated utility of COPD patients according to levels of disease severity was as follows: Mild = 0.820 (95% CI: 0.800–0.840); Moderate = 0.801 (95% CI: 0.794–0.809); Severe = 0.774 (95% CI: 0.767–0.782); and Very Severe = 0.743 (95% CI: 0.730–0.756). The correlation between increasing disease severity and decreasing patients' utility demonstrated the internal validity of the data.

Conclusion This analysis provides estimates of utility by COPD disease severity based on one of the largest sample sizes used to date, which is essential for cost-utility analyses that help inform healthcare decisions.

1. Kind P et al. "Variations in population health status: results from a United Kingdom national questionnaire survey." *BMJ* 316, no. 7133 (Mar 1998): 736–41.

P85 ASSESSING THE PATIENT EXPERIENCE OF COPD CARE USING AN IPSOS MORI QUESTIONNAIRE AS A PATIENT REPORTED EXPERIENCE MEASURE (PREM)

doi:10.1136/thoraxjnl-2012-202678.327

¹DJ Powrie, ¹M Ali, ¹S Ansari, ¹KG Lingam, ²P Mulley, ³S Hope, ¹AG Davison. ¹Southend University Hospital, Westcliff on Sea, UK; ²GlaxoSmithKline, Stockley Park West, UK; ³Ipsos MORI, London, UK

Patient reported experience measures provide vital information on the experience that patients have regarding their care and thus have become a recent focus of interest. We have developed a questionnaire to assess PREMS in patients with COPD attending a hospital outpatient clinic. The purpose of the questionnaire was to assess whether the processes that are necessary to improve outcomes in COPD had been dealt with in the clinic and understood by the patient. Also to assess in a similar way the understanding of COPD by the patient and whether they were satisfied with the consultation.

Results The questionnaire was completed by 142 new and follow up patients. Results are presented in the table below. 92% of patients had spirometry performed at their visit and 78% had the results explained. Before the consultation 57% of patients thought they had a good understanding, 30% moderate and 13% little or no understanding of their condition. Afterwards these improved to 67%, 23% and 10% respectively. 29% believed that their knowledge of how to reduce exacerbations had increased after the consultation. 87% of patients thought that the length of the review was about right (average 20 minutes). 85% were satisfied overall with the consultation.

Conclusion We have studied COPD care from the patient's perspective. We have found evidence that simple clinician-led measures (such as flu vaccination and spirometry) have been explained either in clinic or previously and understood by the patient. We were less successful in dealing with more complex patient-centred experiences such as understanding of the disease and self management of exacerbations. Following this study we plan to develop a questionnaire dealing with the patient's understanding of their disease that would

Abstract P85 Table 1

During your consultation were you told?	Explained in clinic (%)	Explained before (%)	total
How to access flu vaccination	65	22	87
How to access pneumonia vaccination	46	25	71
How to use your inhalers	59	33	92
How medicines would benefit you	56	27	83
How to access to smoking cessation	69	17	86
How COPD may affect you	43	35	78
What to do if symptoms get worse	20	46	66

be filled in before attending clinic. This would allow areas of concern to the patient to be specifically addressed in the consultation. In addition the questionnaire could be used to provide feedback to individual clinicians on their effectiveness in outpatient clinics.

Cystic Fibrosis: diagnosis to therapy

P86 THE SCREENING AND DIAGNOSIS OF CYSTIC FIBROSIS-RELATED DIABETES IN THE UNITED KINGDOM

doi:10.1136/thoraxjnl-2012-202678.328

¹KL Wickens-Mitchell, ²FJ Gilchrist, ¹W Lenney. ¹Keele University, Keele, UK; ²University Hospital of North Staffordshire, Stoke on Trent, UK

Introduction Cystic fibrosis related diabetes (CFRD) affects 17% of CF patients in the UK and is increasing in prevalence. It has a major detrimental impact on pulmonary function, nutritional status and survival; these effects are frequently seen prior to diagnosis. The UK CF Trust guidelines regarding CFRD screening, diagnosis and management differ from those used in Europe and the USA. We conducted a study to establish current UK clinical practise.

Methods A questionnaire was emailed to consultants at each of the 48 UK CF specialist centres. Data were gathered on the screening and diagnosis of CFRD as well as the personnel involved.

Results Completed questionnaires were returned by 39/48 centres (81%). Only 3/21 (14%) paediatric centres begin screening at 12 years (as per the UK CF Trust guidelines), with the majority; 11/21 (52%) starting to screen children at 10 years (as per the European and USA guidelines). Five centres start screening at a child's first annual review. The most common test used to screen patients for CFRD is the oral glucose tolerance test (OGTT) which is used in 33/39 (85%) centres. However, this tool is only used in isolation by 3/33 (9%) centres. More commonly, results of the OGTT are combined with random blood glucose tests and/or HbA_{1c} measurement. The test most frequently used to diagnose CFRD is home blood glucose monitoring which is undertaken in 32/39 centres (82%). Again this is rarely used in isolation, more commonly combined with HbA_{1c} and/or with the results of a continuous glucose monitoring system (CGMS). CGMS is undertaken for diagnosis in 23/39 centres (59%). The decision to initiate insulin therapy was most often shared between a CF consultant and diabetologist. However, in 4/14 (36%) centres a diabetic nurse specialist had sole responsibility.

Conclusions In UK clinical practise the screening and diagnosis of CFRD is not uniform. Various methods are used and there is poor adherence to UK CF Trust guidelines. However, these guidelines from 2004 are somewhat out-dated and need to be updated to reflect the current best available evidence. This is likely to decrease the variation in practise.

P87 THE IMPACT OF RESPIRATORY VIRUSES AND PULMONARY EXACERBATIONS ON FEV1 DECLINE IN ADULTS WITH CYSTIC FIBROSIS

doi:10.1136/thoraxjnl-2012-202678.329

¹WG Flight, ²KJ Mutton, ¹AK Webb, ¹RJ Bright-Thomas, ¹AM Jones. ¹Manchester Adult Cystic Fibrosis Centre, Manchester, United Kingdom; ²Dept of Virology, Manchester Royal Infirmary, Manchester, United Kingdom

Introduction Viral respiratory infection (VRI) is associated with an increased rate of decline in lung function in children with cystic fibrosis (CF) but the long-term clinical impact of VRI in adults is poorly described. We performed a prospective observational study to determine the effect of VRI on lung function in adults with CF.

Methods 100 adults with CF were followed for 12 months. Patients were seen every two months routinely and also at onset of new respiratory symptoms. Sputum, nose- and throat-swabs were